Why Valeant Pharmaceuticals Intl Inc. Shares Are Down 19% in 2 Days

Analyst David Maris is not a fan of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

The Motley Fool

In a research note published Friday, Wells Fargo analyst David Maris initiated coverage on Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) with an underperform rating, along with a $65-68 target price.

Mr. Maris actually has a long history with Valeant. Back in 2003 he put out a negative report on Valeant’s predecessor company, Biovail. He focused on the company’s explanation that its numbers missed because a truck carrying a large amount of medicine crashed. For this report, he was fired from his job, embroiled in a lawsuit, and shunned by Wall Street. What makes this story especially awful is that he was right about the facts.

So Mr. Maris is certainly worth paying attention to, even though Valeant backers will undoubtedly argue that his experience makes him biased. Below are his main arguments against Valeant.

Accounting issues

Mr. Maris’s main arguments concern Valeant’s “considerable subjectivity” in its financial reports. To illustrate, he points out that receivables have grown far faster than sales over the past several years. He also doubts the validity of Valeant’s cash EPS metric. And he is skeptical about the company’s setting up of deferred-tax asset accounts.

Too much debt

Thanks to its acquisitive history, Valeant has about US$30 billion of debt, and Mr. Maris thinks that this will become a serious burden. In fact, he thinks the company will need to use its entire free cash flow to pay this debt down.

The Walgreens deal

In mid-December, Valeant announced a new distribution deal with Walgreens, one that ideally would plug the revenue gap from the termination of Philidor. Investors initially reacted well to the news, sending Valeant’s shares up by 17%.

But Mr. Maris is not impressed. He claims that Valeant has failed to explain what fees Walgreens will charge to distribute its drugs. He also says Valeant hasn’t shed light on if the volume from Walgreens will make up for Philidor’s absence.

Mr. Maris is probably on to something here. The mere fact that Valeant signed this deal right after the Philidor debacle indicates that Walgreens had the upper hand in negotiations. So those who are expecting the Walgreens deal to plug the gap is probably kidding themselves.

Some positives

In his report, Mr. Davis did acknowledge some positive aspects of Valeant’s business. He cites a number of brands that are performing very well, including Xifaxan, the company’s number one drug. He also notes that the company is well diversified by product line.

That being the case, this is still an incredibly risky stock, one that Mr. Davis thinks is overvalued. So even though the stock has come off a lot since his report was published, this is a name I would stay away from.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals and Wells Fargo and has the following options: short March 2016 $52 puts on Wells Fargo.

More on Investing

jar with coins and plant
Dividend Stocks

How Much to Invest in TC Energy for $142 a Quarter in Dividends

With predictable cash flows, consistent dividend growth, an attractive yield, and clear growth opportunities, TC Energy is ideal for income-seeking…

Read more »

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

Where Could Celestica Stock Be in 5 Years? What the New Outlook Means

Celestica’s ambitious 2027 outlook and accelerating AI infrastructure demand could fuel its next phase of growth, making its recent stock…

Read more »

man in bowtie poses with abacus
Dividend Stocks

How Much Would You Need in SmartCentres to Collect $250 a Month?

SmartCentres can pay an actual monthly distribution. Reaching $250 from it alone would require nearly $45,000 at recent prices.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Stock Market

One ETF or Several? How to Keep Your Investments as Simple as Possible

Here's how choosing the right mix of ETFs could help you simplify your investments while building long-term wealth.

Read more »

ETFs can contain investments such as stocks
Dividend Stocks

1 Top Dividend ETF to Buy to Generate Passive Income

Vanguard's VDY pays monthly with a 0.22% MER and a 3% yield. See what $20,000 could earn, the bank and…

Read more »

groceries get more expensive as inflation rises
Dividend Stocks

2 TSX Giants to Buy for Decades of Growth and Dividends

Royal Bank of Canada (TSX:RY) and another dividend giant worth buying up for decades.

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

2 of the Best ETFs to Buy Now

Looking for the best ETFs to buy now? Explore how XEQT offers global stock exposure while ZAG adds Canadian bonds…

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

A TFSA-Worthy Dividend Stock Paying 5.1% Monthly

Choice Properties could be a great monthly dividend stock for TFSA investors seeking attractive passive income and long-term growth potential.

Read more »